Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis

Megan K. Luther, PharmD¹⁻³; Tristan T. Timbrook, PharmD, MBA, BPCS¹⁻³; Aisling R. Caffrey, PhD, MS¹⁻⁴; David Dosa, MD, MPH³⁻⁴; Thomas P. Lodise, PharmD, PhD⁵; Kerry L. LaPlante, PharmD, FCCP¹⁻⁴

Objectives: The objective of this systematic review and meta-analysis was to assess acute kidney injury with combination therapy of vancomycin plus piperacillin-tazobactam, in general, adult patients and in critically ill adults. Rates of acute kidney injury, time to acute kidney injury, and odds of acute kidney injury were compared with vancomycin monotherapy, vancomycin plus cefepime or carbapenem, or piperacillin-tazobactam monotherapy.

Data Sources: Studies were identified by searching Pubmed, Embase, Web of Science, and Cochrane from inception to April 2017. Abstracts from selected conference proceedings were manually searched.

Data Synthesis: Literature search identified 15 published studies and 17 conference abstracts with at least 24,799 patients. The overall occurrence rate of acute kidney injury was 16.7%, with 22.2% for vancomycin plus piperacillin-tazobactam and 12.9% for comparators. This yielded an overall number needed to harm of 11. Time to acute kidney injury was faster for vancomycin plus piperacillin-tazobactam than vancomycin plus cefepime or carbapenem, but not significantly (mean difference, –1.30; 95% CI, –3.00 to 0.41 d). The odds of acute kidney injury with vancomycin plus piperacillin-tazobactam were increased versus vancomycin monotherapy (odds ratio, 3.40; 95% CI, 2.57–4.50), versus vancomycin plus cefepime or carbapenem (odds ratio, 2.68; 95% CI, 1.83–3.91), and versus piperacillin-tazobactam monotherapy (odds ratio, 2.70; 95% CI, 1.97–3.69). In a small subanalysis of 968 critically ill patients, the odds of acute kidney injury were increased versus vancomycin monotherapy (odds ratio, 9.62; 95% CI, 4.48–20.68), but not significantly different for vancomycin plus cefepime or carbapenem (odds ratio, 1.43; 95% CI, 0.83–2.47) or piperacillin-tazobactam monotherapy (odds ratio, 1.35; 95% CI, 0.86–2.11).

Conclusions: The combination of vancomycin plus piperacillin-tazobactam increased the odds of acute kidney injury over vancomycin monotherapy, vancomycin plus cefepime or carbapenem, and piperacillin-tazobactam monotherapy. Limited data in critically ill patients suggest the odds of acute kidney injury are increased versus vancomycin monotherapy, and mitigated versus the other comparators. Further research in the critically ill population is needed. (Crit Care Med 2018; 46:12–20)

Key Words: acute kidney injury; cefepime; critically ill; piperacillin-tazobactam; vancomycin
Acute kidney injury (AKI) is associated with increased morbidity and mortality (1–4). There are several definitions, but recent consensus documents focus on three: 1) Risk, Injury, Failure, Loss, End-stage (RIFLE) (5); 2) Acute Kidney Injury Network (AKIN) (6); and 3) Kidney Disease: Improving Global Outcomes (KDIGO) (7), which is a combination of the other two definitions. When defined as an increase in serum creatinine of 0.5 mg/dL or greater, one component of the RIFLE definition, AKI increases length of hospital stay by approximately 3.5 days and costs by ~$7500 (1). Mortality is also increased approximately 6.5-fold and increases even more with larger increases in serum creatinine (1). The poor outcomes associated with AKI have also been demonstrated in several studies of critically ill patients (2, 4, 8, 9), with rates of AKI in ICU populations ranging from 28% to 67% (8, 10–12).

Historically, risk of AKI during vancomycin treatment has been widely known and ranged from 5% to 7% (13, 14). Increases in doses and target trough concentrations may be responsible for the recent observed increases in rates of vancomycin-associated AKI, up to 43% (15–19). Although there is some controversy over whether vancomycin monotherapy can cause nephrotoxicity or AKI in an otherwise healthy person, it is generally agreed that concomitant nephrotoxic agents, as well as many comorbid conditions and drug exposure factors, such as dosing, trough concentrations, and duration of therapy, increase this risk (15, 20–22). Risk factors, including vasoactive medications, hypotension, and increased disease severity, are often associated with the critically ill population, where vancomycin is prevalent (23, 24).

Since 2011, there have been multiple studies demonstrating an increase in AKI with combination therapy of vancomycin plus piperacillin-tazobactam (25–56). Vancomycin plus piperacillin-tazobactam is one of the most commonly used combinations of antimicrobials with widespread use in hospitals (57). Rates of AKI in these initial studies ranged from 18% to 49% with the combination (32, 33, 49, 52). Initial reports were small observational studies, often in very specific patient populations, such as diabetic patients with osteomyelitis or patients in the surgical ICU (33, 41, 52). Given increases in mortality and length of stay associated with AKI and the widespread use of vancomycin plus piperacillin-tazobactam, this combination could have a substantial effect on patient outcomes.

This systematic review and meta-analysis was performed to determine the association between vancomycin plus piperacillin-tazobactam and AKI in adults. AKI rates and odds ratios (OR) were calculated for each comparator: vancomycin alone, vancomycin plus other beta-lactams (cefepime or carbapenem), and piperacillin-tazobactam alone. Time to AKI was evaluated to determine whether onset occurred faster with the combination of vancomycin plus piperacillin-tazobactam. Additionally, a subanalysis in critically ill patients was performed for each comparator group to determine if the effects were enhanced or mitigated.

METHODS

Literature Search
Two authors (M.K.L., T.T.T.) independently performed a systematic literature review. PubMed, Embase, Web of Science, and Cochrane were systematically searched from inception to April 15, 2017. Keywords of vancomycin, piperacillin, and kidney, renal, nephrotoxicity, nephropathy, nephritis, safety, or adverse were used. Reference lists of included studies were manually searched for relevant studies.

Study Selection
Titles and abstracts of potentially relevant studies were reviewed. Randomized, or observational reports were eligible to be included in the meta-analysis if they 1) enrolled adult patients (≥ 18 yr old), 2) included patients on concomitant vancomycin and piperacillin-tazobactam and either vancomycin alone, vancomycin plus another beta-lactam, or piperacillin-tazobactam alone, and 3) nephrotoxicity/AKI rates or ORs could be extracted for each group. All definitions of AKI that referenced specific changes in serum creatinine (e.g., 1.5-fold or 0.5 mg/dL increase), urine output, or need for dialysis/renal replacement therapy were included. Studies that used a definition referring to an upper limit of normal serum creatinine were excluded. Pediatric studies, case reports/series, and articles not in English were excluded. Abstracts from conference proceedings were included. In addition to conference abstracts included in the database search, we manually searched abstract collections from IDweek, Interscience Conference on Antimicrobial Agents and Chemotherapy, Kidney Week, American College of Clinical Pharmacy, Society of Critical Care Medicine, and American Society of Health-System Pharmacists midyear meeting for full text abstracts using the keywords vancomycin, piperacillin, or zosyn. Data from final posters were used when available online. Authors were not contacted for missing data.

Study Quality
The quality of included studies was assessed using the Newcastle-Ottawa quality assessment score (NOS) (58). Each study was scored from 0 to 9, based on eight criteria covering selection of cohort, comparability of groups, and outcome. Discrepancies between the two authors were resolved by consensus.

Data Extraction
Data collected from each study included author, publication year, study design, location and dates of enrollment, inclusion and exclusion criteria, definition of AKI used, medications included, and measures of outcomes (e.g., AKI rates).

Outcomes
The primary outcome for the meta-analysis was AKI, as defined by the individual study. Most studies used AKIN, RIFLE, KDIGO, or vancomycin consensus guidelines to define AKI or nephrotoxicity (5–7, 20). The percentage of patients developing AKI with each drug regimen were calculated and used to calculate an overall number needed to harm. Time to AKI was extracted from studies when provided for groups of interest.
Median and interquartile range were converted to mean and standard deviation (SD) using methods from Wan et al (59). A secondary analysis was performed for critically ill patients, defined as being in an ICU, to determine whether the impact of these medications on AKI was mitigated or enhanced in ICUs.

Statistical Analysis

AKI rate differences, and corresponding p values, as well as the number needed to harm were calculated from OpenEpi (60). Meta-analysis was performed in Review Manager 5.3 (RevMan; Cochrane Library, Oxford, United Kingdom) (61). Pooled ORs and 95% CIs were calculated using the generic inverse variance random effects model for each comparator (vancomycin monotherapy, piperacillin-tazobactam monotherapy, or vancomycin plus cefepime or a carbapenem). Crude ORs were calculated from the raw AKI rates in each study. Adjusted ORs were used over the crude OR when provided for the groups of interest. Mean difference in time to AKI was calculated using a random effects model. Publication bias was assessed using funnel plots. Heterogeneity was assessed by F statistic and Cochran’s Q. A p value of less than 0.10 was considered statistically significant since Cochran’s Q has low power. Sensitivity analyses were performed 1) by removing each study individually in order to determine whether an individual report has higher contribution to the heterogeneity or overall effect estimate 2), analyzing published studies separately from abstracts 3), including only high quality reports (Newcastle-Ottawa score ≥ 7), and 4) including only reports that used methods to control for confounding. Reporting for this meta-analysis is in accordance with the Meta-Analysis of Observational Studies in Epidemiology guidance (62).

RESULTS

A flow diagram of the literature search is shown in Figure 1. The search identified 15 published studies meeting inclusion and exclusion criteria for the meta-analysis (Table 1, Supplemental Digital Content 1, http://links.lww.com/CCM/C921). Six studies compared vancomycin plus piperacillin-tazobactam with vancomycin monotherapy (26, 27, 30, 32, 37, 39), whereas eight studies compared with vancomycin plus cefepime or a carbapenem (25, 28, 29, 33, 34, 36, 38, 39) and four compared with piperacillin-tazobactam monotherapy (30, 31, 35, 37). Three studies had multiple comparisons (30, 37, 39). One study was excluded from the vancomycin plus cefepime analysis because the data overlapped another study (34, 39). We also identified 17 abstracts from conference proceedings (Table 2, Supplemental Digital Content 2, http://links.lww.com/CCM/C922) (40–56), with a total number of patients from published studies and conference abstracts of at least 24,799. There is overlap between separate studies from the same research groups against different comparator antibiotics (34, 37–39). However, patients in overlapping groups were not double-counted, so the total number of patients in Supplemental Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/C921) and Supplemental Table 2 (Supplemental Digital Content 2, http://links.lww.com/CCM/C922) is greater than this number.

There were significant differences in study populations evaluated. Mean age ranged from 48 to 74, and severity of illness differed between studies (29, 30, 36, 52). There were also differences among the exclusion criteria for studies which included varying serum creatinine values of greater than 1.2 mg/dL (34), greater than 1.5 mg/dL (26, 40), greater than 2.0 mg/dL (27), and greater than 2.5 mg/dL (36), or creatinine clearance values of less than 30 mL/min (26), less than 40 mL/min (33), and less than 60 mL/min (28, 63) (Table 1, Supplemental Digital Content 1, http://links.lww.com/CCM/C921; and Supplemental Table 2, Supplemental Digital
Vancomycin plus piperacillin-tazobactam increased the odds of AKI versus each comparator. The odds of AKI increased with vancomycin plus piperacillin-tazobactam versus vancomycin monotherapy (OR, 3.40; 95% CI, 2.57–4.50) (Fig. 4A). Compared with vancomycin plus cefepime or carbapenem, the OR for AKI with vancomycin plus piperacillin-tazobactam was 2.68 (95% CI, 1.83–3.91) (Fig. 4B) and compared with piperacillin-tazobactam monotherapy, the OR was 2.70 (95% CI, 1.97–3.69) (Fig. 4C). Heterogeneity was significant for each of these analyses ($I^2 ≥ 53%$; $p ≤ 0.01$). In an analysis separating studies with vancomycin plus cefepime and vancomycin plus carbapenem, no significant differences in the OR for AKI were found (2.39 vs 3.46, respectively, $p = 0.33$) (Supplemental Fig. 1, Supplemental Digital Content 3, http://links.lww.com/CCM/C923; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929).

Among critically ill populations, the odds of AKI vary depending on the comparator antibiotic. One recent study of the critically ill found no significant increase in AKI with the combination of vancomycin and piperacillin-tazobactam compared with vancomycin plus cefepime (29). Another study found an almost 10-fold increase compared with vancomycin monotherapy in patients from a surgical ICU (52). Two studies in patients in burn units also found seven- to 10-fold increases in AKI over vancomycin monotherapy (46, 54). The meta-analysis of critically ill patients included three studies comparing to vancomycin alone, three studies comparing to vancomycin plus cefepime or carbapenem, and one study comparing to piperacillin-tazobactam alone, for a total of 968 patients. In the subset of critically ill patients, the odds of AKI compared with vancomycin were increased (OR, 9.62; 95% CI, 4.48–20.68) (Fig. 5). The odds of AKI compared with vancomycin plus cefepime or carbapenem or piperacillin-tazobactam alone were decreased and no longer significantly different.

Multiple sensitivity analyses were conducted, which resulted in overall similar ORs. In a sensitivity analysis evaluating the removal of individual studies, only Rutter et al (37) comparing vancomycin plus piperacillin-tazobactam to vancomycin alone resulted in significant changes in the heterogeneity, which accounted for over two-thirds of patients in this analysis, with a relatively small CI. In sensitivity analyses looking at published studies versus abstracts, the ORs for published articles were similar to the overall analysis (published and abstracts) for vancomycin monotherapy and vancomycin plus cefepime or carbapenem, but the heterogeneity was lower for published studies ($p > 0.10$) (Supplemental Fig. 2, Supplemental Digital Content 4, http://links.lww.com/CCM/C924; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929). The point estimate for published manuscripts was slightly lower for piperacillin-tazobactam (1.89 vs 2.70), but heterogeneity was still significant ($I^2 = 59%$; $p = 0.06$). In the quality assessment, the range of NOS scores was between 3 and 9 (maximum of 9; Supplemental Table 3, Supplemental Digital Content 5, http://links.lww.com/CCM/C925). Sensitivity analyses using

Figure 2. Scatterplot of percentage of patients with acute kidney injury (AKI) in included studies. PT = piperacillin-tazobactam monotherapy. VAN = vancomycin monotherapy. VAN + FEP/CAR = vancomycin plus cefepime or carbapenem. VAN + PT = vancomycin plus piperacillin-tazobactam.
only high quality reports with a NOS greater than or equal to 7 and one with reports that used methods to control for confounding demonstrated similar ORs to the primary analysis which included all reports (Supplemental Fig. 3, Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929). Of note, all high quality reports used methods to control confounding. In these analyses, only two studies compared vancomycin plus piperacillin-tazobactam to piperacillin-tazobactam monotherapy. Between-study heterogeneity remained significant (Supplemental Fig. 4, Supplemental Digital Content 7, http://links.lww.com/CCM/C927; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929).

**DISCUSSION**

This systematic review and meta-analysis demonstrated increased odds of AKI with concomitant vancomycin and piperacillin-tazobactam use. This increase was observed with increased odds of AKI with concomitant vancomycin and piperacillin-tazobactam use. This increase was observed with concomitant vancomycin and piperacillin-tazobactam therapy. Vancomycin plus cefepime or a carbapenem, and vancomycin plus piperacillin-tazobactam monotherapy. Between-study heterogeneity remained significant (Supplemental Fig. 3, Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929).

Among the critically ill adult population, there was wide variability in the odds of AKI, depending on the comparator medication (Fig. 5). Within each comparator group, however, there was no heterogeneity observed. The meta-analysis subgroup of critically ill patients is relatively small, since not all studies included data specifically on ICU patients, but was able to demonstrate statistically significant results for vancomycin plus piperacillin-tazobactam versus vancomycin monotherapy (OR, 9.62; 95% CI, 4.48–20.68). Only seven studies included critically ill data, with a total of 968 patients. None of these studies included adjusted ORs for these patients, so it is possible that risk factors for kidney injury, such as severity or type of illness, contrast media, hypotension, or other factors, are responsible or playing a role in these cases of AKI. Randomized controlled trials comparing monotherapy and combination therapy are unlikely, but by comparing vancomycin plus piperacillin-tazobactam to vancomycin plus cepheim or carabenem, some of the concerns about confounding can be limited. These patients would theoretically have similar risks of sepsis or ICU admission; however, this may not eliminate potential confounding entirely. The critically ill subset of this meta-analysis with vancomycin plus cepheim or carabenem did not demonstrate significant differences in AKI from vancomycin plus piperacillin-tazobactam (OR, 1.43; 95% CI, 0.83–2.47) which may indicate that these patients are similar or have more similar risks for AKI. Only one study in the literature search included data on AKI in critically ill patients on piperacillin-tazobactam monotherapy, in patients with intra-abdominal infections (35). This study was included as a comparator in the critically ill subgroup analysis but should be considered carefully due to the limited size and lack of similar studies in the meta-analysis. The analysis demonstrates possible differential effects in ICU patients, which should be investigated in future studies. In addition, prospective randomized controlled trials investigating vancomycin plus piperacillin-tazobactam versus vancomycin plus cepheim would be helpful in determining the true effect size.

**Figure 3.** Mean difference in time (d) to acute kidney injury (AKI) for vancomycin plus piperacillin-tazobactam (VAN + PT) versus vancomycin plus cefepime (VAN + FEP). AAC = antimicrobial agents and chemotherapy, IV = inverse variance.

- **Table 1.** Study or subgroup | Mean (d) | SD | Total | Mean (d) | SD | Total | Weight | Mean difference | IV, Random, 95% CI (days) | Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929.

- **Table 2.** Study or subgroup | Mean (d) | SD | Total | Mean (d) | SD | Total | Weight | Mean difference | IV, Random, 95% CI (days) | Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929.

- **Table 3.** Study or subgroup | Mean (d) | SD | Total | Mean (d) | SD | Total | Weight | Mean difference | IV, Random, 95% CI (days) | Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929.

- **Table 4.** Study or subgroup | Mean (d) | SD | Total | Mean (d) | SD | Total | Weight | Mean difference | IV, Random, 95% CI (days) | Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929.

- **Table 5.** Study or subgroup | Mean (d) | SD | Total | Mean (d) | SD | Total | Weight | Mean difference | IV, Random, 95% CI (days) | Supplemental Digital Content 6, http://links.lww.com/CCM/C926; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929.
Given the number needed to harm of 11, along with the widespread use of this combination therapy, AKI with vancomycin plus piperacillin-tazobactam likely has a large impact on patient outcomes with the increased length of stay, costs, and mortality associated with AKI (1). Although AKI with vancomycin is typically reversible, even transient AKI in critically ill patients has been associated with increased mortality (8). Daily ICU costs can also be much higher, which would increase the costs above the $7,500 previously quoted for hospital-wide patients (1). Reducing the use and duration of vancomycin and piperacillin-tazobactam could reduce AKI incidence (31, 34). Strategies to aid in this aim include using antimicrobial

![Figure 4. Forest plot demonstrating the odds of acute kidney injury (AKI) with vancomycin plus piperacillin-tazobactam (VAN + PT) versus vancomycin monotherapy (VAN) (A), vancomycin plus cefepime or a carbapenem (VAN + FEP/CAR) (B), and piperacillin-tazobactam monotherapy (PT) (C).](image)

*Adjusted odds ratio. AAC = antimicrobial agents and chemotherapy, IV = inverse variance.
stewardship policies, such as protocols for using alternative antibiotics when appropriate, institution-specific guidance on when combination therapy is necessary, and institutional antibiograms for susceptibility. Other stewardship programs have used antibiotic restriction and time-outs to decrease use of vancomycin and/or piperacillin-tazobactam (31, 65). Stewardship programs have thus demonstrated reduced rates of AKI (27). Most studies in the meta-analysis required at least 48–72 hours of antibiotic therapy to be included, and the analysis of time to AKI noted an onset within 8 days. Rapid diagnostic test implementation in hospital settings may help to deescalate from vancomycin plus piperacillin-tazobactam therapy sooner, potentially avoiding AKI (66). Unfortunately, time to AKI was not available for studies in ICU populations, so further research is needed.

The mechanism of increased AKI with vancomycin and piperacillin-tazobactam is not known. Though there are reports of AKI or acute interstitial nephritis with cefepime, carbapenems, and other non-piperacillin-tazobactam beta-lactams, these reports are rare compared with the studies of piperacillin-tazobactam (67–69). One study also noted that piperacillin-tazobactam had the lowest renal recovery rate (measured by change in creatinine clearance) among beta-lactams tested, indicating possible kidney hazard with piperacillin-tazobactam (70). Piperacillin-tazobactam has not traditionally been considered a nephrotoxic medication; however, several studies, and the pooled percentages of AKI we calculated, demonstrated increased odds of AKI with piperacillin-tazobactam (74–78). Although it is not clear from these studies what happens in the bloodstream, precipitation of these medications could lead to kidney damage.

There are other limitations to this analysis. These observational studies are subject to possible bias such as confounding by indication, since patients receiving different therapies are likely different in other ways. There is also the possibility of misclassification bias; it is not clear in all the studies whether the vancomycin alone group received other antibiotics (i.e., not piperacillin-tazobactam) that may include cefepime or carbapenems. The results, however, of the meta-analyses for vancomycin alone and vancomycin plus cefepime or carbapenem were similar, and any changes from misclassification would likely be small. We cannot rule out publication bias among the included reports (Supplemental Fig. 2, Supplemental Digital Content 8, http://links.lww.com/CCM/C924; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929). Larger studies and studies indicating a higher risk of AKI with combinations of vancomycin and piperacillin-tazobactam may be more likely to be published than those not demonstrating a significant difference. In the funnel plots in Supplemental Fig. 5 (Supplemental Digital Content 8, http://links.lww.com/CCM/C928; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/C929), this is indicated by the lack of studies with low ORs and higher ses. We chose to present the results of conference abstracts to see the impact on the overall OR and compare the results. Of course, conference abstracts have limitations, including that they may have been edited before final presentation, they are not always peer-reviewed, and some information may be missing. Additionally, not all abstracts from the included conferences could be accessed in the collections searched. Our results, including abstracts from well-known infectious diseases, critical care, and pharmacy conferences, however, indicated similar odds of AKI as published studies.
CONCLUSION
Available literature suggests that the combination of vancomycin plus piperacillin-tazobactam increases the odds of AKI approximately three-fold. This increased risk was present versus vancomycin monotherapy, piperacillin-tazobactam monotherapy, and vancomycin plus cefepime or carbapenem combination therapy. Although small, the analysis of critically ill patients suggests the odds of AKI with vancomycin plus piperacillin-tazobactam are increased over vancomycin monotherapy, but mitigated versus vancomycin plus cefepime or carbapenem. Further research in critically ill patients is needed.

REFERENCES


47. Garst MJ: Does vancomycin or piperacillin-tazobactam have the greater potential for acute kidney injury? 4–176. ASHP Midyear clinical meeting, Anaheim, CA, December 8, 2014


